Makoto Nishio

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 52

Top Topics

Tyrosine Kinase

Clinical Practice

Epidermal Growth Factor Receptor

Small Cell Lung Cancer

Top Venues

Thoracic cancer

Cancer research communications

Cancer medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Ayu Kiritani, Yoshiaki Amino, Ken Uchibori, Takahiro Akita, Yuhei Harutani, Shinsuke Ogusu, Ryosuke Tsugitomi, Ryo Manabe, Ryo Ariyasu, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio
Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion. Thoracic cancer (2024)
Takahiro Akita, Ryo Ariyasu, Sho Kakuto, Keiki Miyadera, Ayu Kiritani, Ryosuke Tsugitomi, Yoshiaki Amino, Ken Uchibori, Satoru Kitazono, Noriko Yanagitani, Sadatomo Tasaka, Makoto Nishio
Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers. Thoracic cancer 15 (10) (2024)
Takahiro Akita, Ryo Ariyasu, Sho Kakuto, Keiki Miyadera, Ayu Kiritani, Ryosuke Tsugitomi, Yoshiaki Amino, Ken Uchibori, Satoru Kitazono, Noriko Yanagitani, Sadatomo Tasaka, Makoto Nishio
Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers. Thoracic cancer (2024)
Makoto Nishio, Shuji Murakami, Hiasto Kawakami, Kyoichi Okishio, Motohiro Tamiya, Haruki Kobayashi, Daichi Fujimoto, Shunichi Sugawara, Toshiyuki Kozuki, Yuko Oya, Hiroki Izumi, Takayuki Shiroyama, Miyako Satouchi, Noboru Yamamoto, Shota Kaname, Daiko Matsuoka, Yohei Otake, Takao Takase, Taro Semba, Koichi Azuma
Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort. Cancer research communications 4 (1) (2024)
Makoto Nishio, Shuji Murakami, Hiasto Kawakami, Kyoichi Okishio, Motohiro Tamiya, Haruki Kobayashi, Daichi Fujimoto, Shunichi Sugawara, Toshiyuki Kozuki, Yuko Oya, Hiroki Izumi, Takayuki Shiroyama, Miyako Satouchi, Noboru Yamamoto, Shota Kaname, Daiko Matsuoka, Yohei Otake, Takao Takase, Taro Semba, Koichi Azuma
Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort. Cancer research communications 4 (1) (2024)
Ayu Kiritani, Yoshiaki Amino, Ken Uchibori, Takahiro Akita, Yuhei Harutani, Shinsuke Ogusu, Ryosuke Tsugitomi, Ryo Manabe, Ryo Ariyasu, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio
Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion. Thoracic cancer 15 (5) (2024)
Takahiro Akita, Ryo Ariyasu, Sho Kakuto, Keiki Miyadera, Ayu Kiritani, Ryosuke Tsugitomi, Yoshiaki Amino, Ken Uchibori, Satoru Kitazono, Noriko Yanagitani, Sadatomo Tasaka, Makoto Nishio
Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers. Thoracic cancer 15 (10) (2024)
Takahiro Akita, Ryo Ariyasu, Sho Kakuto, Keiki Miyadera, Ayu Kiritani, Ryosuke Tsugitomi, Yoshiaki Amino, Ken Uchibori, Satoru Kitazono, Noriko Yanagitani, Sadatomo Tasaka, Makoto Nishio
Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers. Thoracic cancer 15 (10) (2024)
Makoto Nishio, Shuji Murakami, Hiasto Kawakami, Kyoichi Okishio, Motohiro Tamiya, Haruki Kobayashi, Daichi Fujimoto, Shunichi Sugawara, Toshiyuki Kozuki, Yuko Oya, Hiroki Izumi, Takayuki Shiroyama, Miyako Satouchi, Noboru Yamamoto, Shota Kaname, Daiko Matsuoka, Yohei Otake, Takao Takase, Taro Semba, Koichi Azuma
Phase 2 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort. Cancer research communications (2024)
Takahiro Akita, Ryo Ariyasu, Sho Kakuto, Keiki Miyadera, Ayu Kiritani, Ryosuke Tsugitomi, Yoshiaki Amino, Ken Uchibori, Satoru Kitazono, Noriko Yanagitani, Sadatomo Tasaka, Makoto Nishio
Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers. Thoracic cancer 15 (10) (2024)
Ayu Kiritani, Yoshiaki Amino, Ken Uchibori, Takahiro Akita, Yuhei Harutani, Shinsuke Ogusu, Ryosuke Tsugitomi, Ryo Manabe, Ryo Ariyasu, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio
Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion. Thoracic cancer 15 (5) (2024)
Ayu Kiritani, Yoshiaki Amino, Ken Uchibori, Takahiro Akita, Yuhei Harutani, Shinsuke Ogusu, Ryosuke Tsugitomi, Ryo Manabe, Ryo Ariyasu, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio
Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion. Thoracic cancer 15 (5) (2024)
Takahiro Akita, Ryo Ariyasu, Sho Kakuto, Keiki Miyadera, Ayu Kiritani, Ryosuke Tsugitomi, Yoshiaki Amino, Ken Uchibori, Satoru Kitazono, Noriko Yanagitani, Sadatomo Tasaka, Makoto Nishio
Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers. Thoracic cancer 15 (10) (2024)
Shunichi Sugawara, Kentaro Tanaka, Fumio Imamura, Nobuyuki Yamamoto, Makoto Nishio, Kyoichi Okishio, Tomonori Hirashima, Hiroshi Tanaka, Tatsuro Fukuhara, Yasuharu Nakahara, Takayasu Kurata, Nobuyuki Katakami, Morihito Okada, Hidehito Horinouchi, Hibiki Udagawa, Kazuo Kasahara, Miyako Satouchi, Hideo Saka, Takaaki Tokito, Yukio Hosomi, Keisuke Aoe, Kazuma Kishi, Kadoaki Ohashi, Takuma Yokoyama, Noriaki Adachi, Kazuo Noguchi, Paul Schwarzenberger, Terufumi Kato
Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non-small-cell lung cancer in KEYNOTE-407. Cancer science (2023)
Tatsuya Yoshida, Toru Kumagai, Ryo Toyozawa, Ryohei Katayama, Makoto Nishio, Takashi Seto, Koichi Goto, Nobuyuki Yamamoto, Yuichiro Ohe, Kentarou Kudou, Takayuki Asato, Pingkuan Zhang, Kazuhiko Nakagawa
Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial. Cancer science (2023)
Koichi Goto, Yoshimasa Shiraishi, Haruyasu Murakami, Hidehito Horinouchi, Ryo Toyozawa, Masayuki Takeda, Makiko Uno, Nigel Crawford, Joseph McGill, Takeshi Jimbo, Masato Ishigami, Gensuke Takayama, Shintaro Nakayama, Shoichi Ohwada, Makoto Nishio
Phase 1 study of DS-1205c combined with gefitinib for EGFR mutation-positive non-small cell lung cancer. Cancer medicine (2023)
Shunichi Sugawara, Kentaro Tanaka, Fumio Imamura, Nobuyuki Yamamoto, Makoto Nishio, Kyoichi Okishio, Tomonori Hirashima, Hiroshi Tanaka, Tatsuro Fukuhara, Yasuharu Nakahara, Takayasu Kurata, Nobuyuki Katakami, Morihito Okada, Hidehito Horinouchi, Hibiki Udagawa, Kazuo Kasahara, Miyako Satouchi, Hideo Saka, Takaaki Tokito, Yukio Hosomi, Keisuke Aoe, Kazuma Kishi, Kadoaki Ohashi, Takuma Yokoyama, Noriaki Adachi, Kazuo Noguchi, Paul Schwarzenberger, Terufumi Kato
Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non-small-cell lung cancer in KEYNOTE-407. Cancer science (2023)
Tony S K Mok, Pasi A Janne, Makoto Nishio, Silvia Novello, Martin Reck, Conor E Steuer, Yi-Long Wu, Ronan Fougeray, Pang-Dian Fan, Jie Meng, David W Sternberg, Stephen Esker, Helena Alexandra Yu
HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR -mutated NSCLC after a third-generation EGFR TKI. Future oncology (London, England) (2023)
Toshiaki Takahashi, Makoto Nishio, Kazumi Nishino, Yasumasa Yoshiki, Naoko Shiraiwa, Birol Emir, Laura Iadeluca, Yasushi Yatabe, Kazuto Nishio
Real-world study of next-generation sequencing diagnostic biomarker testing for patients with lung cancer in Japan. Cancer science (2023)
Yoshiaki Amino, Siew-Kee Low, Hironori Ninomiya, Ayu Kiritani, Keiki Miyadera, Sho Kakuto, Takahiro Akita, Ryosuke Tsugitomi, Ryo Ariyasu, Ken Uchibori, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio
Clinical characteristics of patients with KRAS mutation detected by liquid biopsy. Thoracic cancer (2023)
Toshiaki Takahashi, Makoto Nishio, Kazumi Nishino, Yasumasa Yoshiki, Naoko Shiraiwa, Birol Emir, Laura Iadeluca, Yasushi Yatabe, Kazuto Nishio
Real-world study of next-generation sequencing diagnostic biomarker testing for patients with lung cancer in Japan. Cancer science (2023)
Makoto Nishio, Terufumi Kato, Ryo Toyozawa, Toyoaki Hida
Management of Peripheral Edema in Patients with MET Exon 14-Mutated Non-small Cell Lung Cancer Treated with Small Molecule MET Inhibitors. Targeted oncology 17 (5) (2022)
Shinya Uematsu, Satoru Kitazono, Hisashi Tanaka, Ryota Saito, Yosuke Kawashima, Fumiyoshi Ohyanagi, Takehiro Tozuka, Tsugitomi Ryosuke, Toshio Sakatani, Atsushi Horiike, Takahiro Yoshizawa, Masafumi Saiki, Yuichi Tambo, Junji Koyama, Masaki Kanazu, Keita Kudo, Yuko Tsuchiya-Kawano, Noriko Yanagitani, Makoto Nishio
Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021-01). Thoracic cancer (2022)
Julie R Brahmer, Jong-Seok Lee, Tudor-Eliade Ciuleanu, Reyes Bernabe Caro, Makoto Nishio, Laszlo Urban, Clarisse Audigier-Valette, Lorena Lupinacci, Randeep Sangha, Adam Pluzanski, Jacobus Burgers, Mauricio Mahave, Samreen Ahmed, Adam J Schoenfeld, Luis G Paz-Ares, Martin Reck, Hossein Borghaei, Kenneth J O'Byrne, Ravi G Gupta, Judith Bushong, Li Li, Steven I Blum, Laura J Eccles, Suresh R Ramalingam
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer in CheckMate 227. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Takuya Sakashita, Noriko Yanagitani, Sumie Koike, Siew-Kee Amanda Low, Satoshi Takagi, Satoko Baba, Kengo Takeuchi, Makoto Nishio, Naoya Fujita, Ryohei Katayama
Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK-rearranged non-small cell lung cancer. Cancer science 113 (11) (2022)
Hisashi Tanaka, Hiroaki Sakamoto, Takahiro Akita, Fumiyoshi Ohyanagi, Yosuke Kawashima, Yuichi Tambo, Azusa Tanimoto, Atsushi Horiike, Eisaku Miyauchi, Yuko Tsuchiya-Kawano, Noriko Yanagitani, Makoto Nishio
Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non-small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020-02). Thoracic cancer 13 (10) (2022)
Toshiaki Takahashi, Kazuko Sakai, Hirotsugu Kenmotsu, Kiyotaka Yoh, Haruko Daga, Tatsuo Ohira, Tsuyoshi Ueno, Tadashi Aoki, Hidetoshi Hayashi, Koji Yamazaki, Yukio Hosomi, Toyofumi F Chen-Yoshikawa, Norihito Okumura, Yuichi Takiguchi, Akimasa Sekine, Tomohiro Haruki, Hiromasa Yamamoto, Yuki Sato, Hiroaki Akamatsu, Takashi Seto, Sho Saeki, Kenji Sugio, Makoto Nishio, Hidetoshi Inokawa, Nobuyuki Yamamoto, Kazuto Nishio, Masahiro Tsuboi
Predictive value of EGFR mutation in non-small-cell lung cancer patients treated with platinum doublet postoperative chemotherapy. Cancer science (2021)
Ken Uchibori, Natsuki Takano, Ryo Manabe, Ryosuke Tsugitomi, Shinsuke Ogusu, Takehiro Tozuka, Hiroaki Sakamoto, Hiroshi Yoshida, Yoshiaki Amino, Ryo Ariyasu, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio
Clinical influence of switching companion diagnostic tests for EGFR-TKs from Therascreen to Cobas v2. Thoracic cancer 12 (6) (2021)
Pasi A Janne, Christina Baik, Wu-Chou Su, Melissa L Johnson, Hidetoshi Hayashi, Makoto Nishio, Dong Wan Kim, Marianna Koczywas, Kathryn A Gold, Conor E Steuer, Haruyasu Murakami, James Chih-Hsin Yang, Sang-We Kim, Michele Vigliotti, Rong Shi, Zhenhao Qi, Yang Qiu, Lihui Zhao, David Sternberg, Channing Yu, Helena A Yu
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer. Cancer discovery (2021)
Hiroaki Sakamoto, Noriko Yanagitani, Ryo Manabe, Ryosuke Tsugitomi, Shinsuke Ogusu, Takehiro Tozuka, Hiroshi Yoshida, Yoshiaki Amino, Ryo Ariyasu, Ken Uchibori, Satoru Kitazono, Sadatomo Tasaka, Makoto Nishio
Characteristics of central nervous system progression in non-small cell lung cancer treated with crizotinib or alectinib. Cancer reports (Hoboken, N.J.) (2021)
Makoto Nishio, Haruhiro Saito, Koichi Goto, Satoshi Watanabe, Naoko Sueoka-Aragane, Yusuke Okuma, Kazuo Kasahara, Kenichi Chikamori, Yuki Nakagawa, Tomohisa Kawakami
IMpower132: Atezolizumab plus platinum-based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients. Cancer science 112 (4) (2021)
Takashi Seto, Kadoaki Ohashi, Shunichi Sugawara, Makoto Nishio, Masayuki Takeda, Keisuke Aoe, Sanae Moizumi, Satoshi Nomura, Takeshi Tajima, Toyoaki Hida
Capmatinib in Japanese patients with MET exon 14 skipping-mutated or MET-amplified advanced NSCLC: GEOMETRY mono-1 study. Cancer science 112 (4) (2021)
Kazuhiko Nakagawa, Ernest Nadal, Edward B Garon, Makoto Nishio, Takashi Seto, Nobuyuki Yamamoto, Keunchil Park, Jin-Yuan Shih, Luis Paz-Ares, Bente Frimodt-Moller, Annamaria H Zimmermann, Sameera Wijayawardana, Carla Visseren-Grul, Martin Reck, null null
RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Ryo Ariyasu, Ken Uchibori, Takaaki Sasaki, Mika Tsukahara, Kazuma Kiyotani, Ryohei Yoshida, Yusuke Ono, Satoru Kitazono, Hironori Ninomiya, Yuichi Ishikawa, Yusuke Mizukami, Noriko Yanagitani, Naoya Fujita, Makoto Nishio, Ryohei Katayama
Monitoring epidermal growth factor receptor C797S mutation in Japanese non-small cell lung cancer patients with serial cell-free DNA evaluation using digital droplet PCR. Cancer science 112 (6) (2021)
Hidehito Horinouchi, Naoyuki Nogami, Hideo Saka, Makoto Nishio, Takaaki Tokito, Toshiaki Takahashi, Kazuo Kasahara, Yoshihiro Hattori, Eiki Ichihara, Noriaki Adachi, Kazuo Noguchi, Fabricio Souza, Takayasu Kurata
Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan Study. Cancer science 112 (8) (2021)
Stephen V Liu, Martin Reck, Aaron S Mansfield, Tony Mok, Arnaud Scherpereel, Niels Reinmuth, Marina Chiara Garassino, Javier De Castro Carpeño, Raffaele Califano, Makoto Nishio, Francisco Orlandi, Jorge Alatorre-Alexander, Ticiana A Leal, Ying Cheng, Jong-Seok Lee, Sivuonthanh Lam, Mark McCleland, Yu Deng, See Phan, Leora Horn
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (6) (2021)
Ryo Ariyasu, Noriko Yanagitani, Kenichi Tadokoro, Toshikazu Yamaguchi, Ken Uchibori, Satoru Kitazono, Naoya Fujita, Ryohei Katayama, Makoto Nishio
Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms. Cancer chemotherapy and pharmacology 86 (4) (2020)
Makoto Nishio, Takashi Seto, Martin Reck, Edward B Garon, Chao-Hua Chiu, Kiyotaka Yoh, Fumio Imamura, Keunchil Park, Jin-Yuan Shih, Carla Visseren-Grul, Bente Frimodt-Moller, Annamaria Zimmermann, Gosuke Homma, Sotaro Enatsu, Kazuhiko Nakagawa, null null
Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY. Cancer science 111 (12) (2020)
Ryo Ariyasu, Ken Uchibori, Hironori Ninomiya, Shinsuke Ogusu, Ryosuke Tsugitomi, Ryo Manabe, Hiroaki Sakamaoto, Takehiro Tozuka, Hiroshi Yoshida, Yoshiaki Amino, Satoru Kitazono, Noriko Yanagitani, Kengo Takeuchi, Makoto Nishio
Feasibility of next-generation sequencing test for patients with advanced NSCLC in clinical practice. Thoracic cancer 12 (4) (2020)
Makoto Nishio, Terufumi Kato, Seiji Niho, Noboru Yamamoto, Toshiaki Takahashi, Naoyuki Nogami, Hiroyasu Kaneda, Yuka Fujita, Keith Wilner, Mizuki Yoshida, Mitsuhiro Isozaki, Shinsuke Wada, Fumito Tsuji, Kazuhiko Nakagawa
Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer. Cancer science 111 (5) (2020)
Kazuko Sakai, Masahiro Tsuboi, Hirotsugu Kenmotsu, Takeharu Yamanaka, Toshiaki Takahashi, Koichi Goto, Haruko Daga, Tatsuo Ohira, Tsuyoshi Ueno, Tadashi Aoki, Kazuhiko Nakagawa, Koji Yamazaki, Yukio Hosomi, Koji Kawaguchi, Norihito Okumura, Yuichi Takiguchi, Akimasa Sekine, Tomohiro Haruki, Hiromasa Yamamoto, Yuki Sato, Hiroaki Akamatsu, Takashi Seto, Sho Saeki, Kenji Sugio, Makoto Nishio, Kazunori Okabe, Nobuyuki Yamamoto, Kazuto Nishio
Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG-TR). Cancer science 112 (1) (2020)
Takashi Seto, Hidetoshi Hayashi, Miyako Satouchi, Yasushi Goto, Seiji Niho, Naoyuki Nogami, Toyoaki Hida, Toshiaki Takahashi, Jun Sakakibara-Konishi, Masahiro Morise, Takashi Nagasawa, Mie Suzuki, Masayuki Ohkura, Kei Fukuhara, Holger Thurm, Gerson Peltz, Makoto Nishio
Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study. Cancer science 111 (10) (2020)
Yusuke Okuma, Yasushi Goto, Fumiyoshi Ohyanagi, Kuniko Sunami, Yoshiro Nakahara, Satoru Kitazono, Keita Kudo, Yuichi Tambo, Shintaro Kanda, Noriko Yanagitani, Atsushi Horiike, Hidehito Horinouchi, Yutaka Fujiwara, Hiroshi Nokihara, Noboru Yamamoto, Makoto Nishio, Yuichiro Ohe, Yukio Hosomi
Phase II trial of S-1 treatment as palliative-intent chemotherapy for previously treated advanced thymic carcinoma. Cancer medicine 9 (20) (2020)
Noriko Yanagitani, Ken Uchibori, Sumie Koike, Mika Tsukahara, Satoru Kitazono, Takahiro Yoshizawa, Atsushi Horiike, Fumiyoshi Ohyanagi, Yuichi Tambo, Shingo Nishikawa, Naoya Fujita, Ryohei Katayama, Makoto Nishio
Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms. Cancer science 111 (3) (2020)
Satoru Kitazono, Kazuko Sakai, Noriko Yanagitani, Ryo Ariyasu, Takahiro Yoshizawa, Yosuke Dotsu, Junji Koyama, Masafumi Saiki, Tomoaki Sonoda, Shingo Nishikawa, Ken Uchibori, Atsushi Horiike, Kazuto Nishio, Makoto Nishio
Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients. Cancer science 110 (10) (2019)
Tomonori Hirashima, Miyako Satouchi, Toyoaki Hida, Makoto Nishio, Terufumi Kato, Hiroshi Sakai, Fumio Imamura, Katsuyuki Kiura, Isamu Okamoto, Kazuo Kasahara, Hirohiko Uchida, Sarah L Vowler, Tetsuya Mitsudomi
Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis. Cancer science 110 (9) (2019)
Makoto Nishio, Toshiaki Takahashi, Hiroshige Yoshioka, Kazuhiko Nakagawa, Tatsuro Fukuhara, Kazuhiko Yamada, Masao Ichiki, Hiroshi Tanaka, Takashi Seto, Hiroshi Sakai, Kazuo Kasahara, Miyako Satouchi, Shi Rong Han, Kazuo Noguchi, Takashi Shimamoto, Terufumi Kato
KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer. Cancer science 110 (3) (2019)
Kimihiro Ito, Makoto Nishio, Masanori Kato, Haruyasu Murakami, Yoshimi Aoyagi, Yuichiro Ohe, Takashige Okayama, Akihiro Hashimoto, Hirokazu Ohsawa, Gotaro Tanaka, Katsumasa Nonoshita, Satoru Ito, Kenichi Matsuo, Kazutaka Miyadera
TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719X. Molecular cancer therapeutics 18 (5) (2019)
Koji Fukuda, Shinji Takeuchi, Sachiko Arai, Ryohei Katayama, Shigeki Nanjo, Azusa Tanimoto, Akihiro Nishiyama, Takayuki Nakagawa, Hirokazu Taniguchi, Takeshi Suzuki, Tadaaki Yamada, Hiroshi Nishihara, Hironori Ninomiya, Yuichi Ishikawa, Satoko Baba, Kengo Takeuchi, Atsushi Horiike, Noriko Yanagitani, Makoto Nishio, Seiji Yano
Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status. Cancer research 79 (7) (2019)
Akihiko Shimomura, Noboru Yamamoto, Shunsuke Kondo, Yutaka Fujiwara, Shigenobu Suzuki, Noriko Yanagitani, Atsushi Horiike, Satoru Kitazono, Fumiyoshi Ohyanagi, Toshihiko Doi, Yasutoshi Kuboki, Akihito Kawazoe, Kohei Shitara, Izumi Ohno, Udai Banerji, Raghav Sundar, Shuichi Ohkubo, Elizabeth M Calleja, Makoto Nishio
First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors. Molecular cancer therapeutics 18 (3) (2019)
Hidehito Horinouchi, Makoto Nishio, Toyoaki Hida, Kazuhiko Nakagawa, Hiroshi Sakai, Naoyuki Nogami, Shinji Atagi, Toshiaki Takahashi, Hideo Saka, Mitsuhiro Takenoyama, Nobuyuki Katakami, Hiroshi Tanaka, Koji Takeda, Miyako Satouchi, Hiroshi Isobe, Makoto Maemondo, Koichi Goto, Tomonori Hirashima, Koichi Minato, Naoki Sumiyoshi, Tomohide Tamura
Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies. Cancer medicine 8 (11) (2019)
Eiji Iwama, Kazuko Sakai, Koichi Azuma, Daijiro Harada, Kaname Nosaki, Katsuyuki Hotta, Makoto Nishio, Takayasu Kurata, Tatsuro Fukuhara, Hiroaki Akamatsu, Koichi Goto, Takayuki Shimose, Junji Kishimoto, Yoichi Nakanishi, Kazuto Nishio, Isamu Okamoto
Exploration of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing. Cancer science 109 (12) (2018)